(Q38175368)

English

Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD).

scientific article published on 03 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 August 2017

Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). (English)

1 reference

Europe PubMed Central

30 August 2017

steatohepatitis

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Iliana Doycheva

1

1 reference

Europe PubMed Central

30 August 2017

Rohit Loomba

2

1 reference

Europe PubMed Central

30 August 2017

language of work or name

0 references

publication date

3 January 2014

1 reference

Europe PubMed Central

30 August 2017

Advances in Therapy

1 reference

Europe PubMed Central

30 August 2017

31

1 reference

Europe PubMed Central

30 August 2017

1

1 reference

Europe PubMed Central

30 August 2017

30-43

1 reference

Europe PubMed Central

30 August 2017

https://scigraph.springernature.com/pub.10.1007/s12325-013-0084-6

0 references

Epidemiology of non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Advances in pediatric nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Hepatocellular ballooning in NASH.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Insulin resistance: a metabolic pathway to chronic liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Cytokines and the pathogenesis of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Mechanisms for insulin resistance: common threads and missing links

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin reverses fatty liver disease in obese, leptin-deficient mice

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin in non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Cellular and molecular mechanisms of metformin: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0084-6

21 January 2018

Identifiers

10.1007/S12325-013-0084-6

1 reference

Europe PubMed Central

30 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38175368&oldid=2092674627"